Swedish healthcare group Sobi has appointed Torbjorn Hallberg as its new general counsel and establishes a new leadership structure.
Hallberg, who joins from Takeda, where he served for seven years, first as senior director and corporate counsel and then more recently as its vice president, general counsel for emerging markets.
He arrives at Sobi will more than 15 years’ experience covering licensing, mergers and acquisitions at pharma groups such as Ferring and Nycomed.
Meanwhile, Sobi has also established a new leadership structure, consisting of chief executive officer Guido Oelkers, chief financial officer Mats-Olof Wallin, general counsel and head of legal affairs Carin Dahlquist (an acting role), head of EMENA Hege Hellström and head of North America Rami Levin.
Also sitting on the new team are Sobi’s head of specialty care Norbert Oppitz, head of medical and scientific affairs Armin Reininger, head of haemophilia Philip Wood and head of research and development and chief medical officer Milan Zdravkovic.
Source: PMLive
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).
